1. Oseltamivir phosphate is an orally administered prodrug. Which enzyme is principally responsible for converting it to its active moiety, oseltamivir carboxylate?
A) Arylacetamide deacetylase in intestinal epithelium
B) Hepatic carboxylesterase 1
C) Cytochrome P450 3A4
D) Inosine monophosphate dehydrogenase
E) Viral neuraminidase
ANSWER: B
Rationale:
Oseltamivir phosphate is an ethyl ester prodrug hydrolyzed principally by hepatic carboxylesterase 1 to oseltamivir carboxylate, the active neuraminidase inhibitor.
Option A: Option A is incorrect: arylacetamide deacetylase activates the baloxavir marboxil prodrug to baloxavir acid, not oseltamivir.
Option C: Option C is incorrect: CYP3A4 does not perform the activating hydrolysis of oseltamivir; it is the enzyme inhibited by ritonavir in the unrelated nirmatrelvir-ritonavir combination.
Option D: Option D is incorrect: inosine monophosphate dehydrogenase is an enzyme inhibited by ribavirin, not one that activates oseltamivir.
Option E: Option E is incorrect: viral neuraminidase is the target oseltamivir carboxylate inhibits, not the enzyme that generates the active drug.
2. A clinician compares the pharmacokinetics of zanamivir and oseltamivir. Which statement most precisely characterizes zanamivir?
A) It is an oral ester prodrug requiring hepatic activation, with renal elimination of the active acid
B) It achieves approximately 80% oral bioavailability and requires dose reduction below a creatinine clearance of 30 mL/min
C) It is a single-dose intravenous neuraminidase inhibitor reserved for hospitalized patients
D) It is a highly polar agent with negligible oral bioavailability, given by inhalation, and the systemic fraction is renally excreted unchanged without dose adjustment for renal impairment
E) It is a prodrug activated by arylacetamide deacetylase and dosed once because of a roughly 79-hour half-life
ANSWER: D
Rationale:
Zanamivir is highly polar with negligible oral bioavailability, so it is delivered by oral inhalation; the small systemic fraction is excreted unchanged by the kidneys and does not require renal dose adjustment.
Option A: Option A is incorrect: the oral ester prodrug with renal elimination of an active acid describes oseltamivir, not zanamivir.
Option B: Option B is incorrect: the roughly 80% oral bioavailability and renal dose reduction below 30 mL/min again describe oseltamivir.
Option C: Option C is incorrect: the single-dose intravenous neuraminidase inhibitor for hospitalized patients is peramivir.
Option E: Option E is incorrect: activation by arylacetamide deacetylase and a roughly 79-hour half-life supporting single dosing describe baloxavir, not zanamivir.
3. Which statement most precisely describes the H275Y neuraminidase substitution?
A) It is the principal clinically significant resistance mutation in N1 neuraminidase (H274Y by N2 numbering), conferring high-level oseltamivir resistance while largely preserving zanamivir susceptibility
B) It is a polymerase acidic subunit substitution that reduces baloxavir binding at the cap-dependent endonuclease
C) It is an M2 transmembrane substitution that abolishes adamantane binding with minimal fitness cost
D) It abolishes neuraminidase enzymatic activity, rendering the virus replication-incompetent
E) It confers complete cross-resistance to oseltamivir, zanamivir, and peramivir simultaneously
ANSWER: A
Rationale:
H275Y is the principal neuraminidase resistance mutation in N1 subtype virus (designated H274Y under N2 numbering); it confers high-level oseltamivir resistance while largely sparing zanamivir because the two drugs contact the active site differently.
Option B: Option B is incorrect: a polymerase acidic subunit substitution reducing baloxavir binding describes PA-I38T, not H275Y.
Option C: Option C is incorrect: an M2 substitution abolishing adamantane binding with minimal fitness cost describes S31N.
Option D: Option D is incorrect: H275Y alters the drug-binding contacts without abolishing enzymatic activity, so the virus remains viable and transmissible.
Option E: Option E is incorrect: cross-resistance is partial, not complete; zanamivir (and peramivir in many cases) susceptibility is characteristically retained.
4. Baloxavir marboxil is administered as a prodrug. Which sequence correctly describes its activation and molecular mechanism?
A) Hepatic carboxylesterase 1 hydrolyzes an ethyl ester to an active carboxylate that competitively blocks neuraminidase
B) Intracellular kinases phosphorylate it to a triphosphate that is incorporated into viral RNA as a chain terminator
C) It requires no activation and binds the M2 ion channel pore to block proton conductance
D) Ribosomal enzymes convert it to an active form that inhibits inosine monophosphate dehydrogenase
E) Arylacetamide deacetylase hydrolyzes it to baloxavir acid, which chelates two divalent metal ions in the polymerase acidic subunit endonuclease active site through its catechol moiety
ANSWER: E
Rationale:
Baloxavir marboxil is hydrolyzed by arylacetamide deacetylase to baloxavir acid; the active acid inhibits the cap-dependent endonuclease of the polymerase acidic subunit by chelating the two divalent metal ions in its active site via a catechol moiety.
Option A: Option A is incorrect: ethyl-ester hydrolysis by carboxylesterase 1 to a neuraminidase-blocking carboxylate describes oseltamivir.
Option B: Option B is incorrect: triphosphate formation and chain termination describe a nucleoside/nucleotide analogue such as remdesivir, not baloxavir.
Option C: Option C is incorrect: an agent needing no activation that blocks the M2 pore describes the adamantanes.
Option D: Option D is incorrect: inhibition of inosine monophosphate dehydrogenase is a ribavirin mechanism, and baloxavir is not activated by ribosomal enzymes.
5. Which statement most accurately characterizes treatment-emergent baloxavir resistance?
A) It is conferred by the H275Y substitution and abolishes susceptibility to all neuraminidase inhibitors
B) It is conferred by the S31N substitution and spreads with negligible fitness cost
C) It is conferred by substitutions at position 38 of the polymerase acidic subunit (most commonly I38T), emerges during treatment more often in pediatric than adult patients, and leaves susceptibility to neuraminidase inhibitors intact
D) It arises only through reassortment of gene segments between human and animal strains
E) It eliminates cap-dependent endonuclease activity, rendering the virus unable to transcribe any messenger RNA
ANSWER: C
Rationale:
Baloxavir resistance is conferred by polymerase acidic subunit position-38 substitutions, most commonly I38T; these emerge during treatment at higher frequency in pediatric than adult patients and reduce baloxavir binding, but because they affect the polymerase rather than neuraminidase, susceptibility to neuraminidase inhibitors is retained.
Option A: Option A is incorrect: H275Y is a neuraminidase mutation affecting oseltamivir, not the baloxavir resistance mechanism, and it does not abolish all neuraminidase inhibitor activity.
Option B: Option B is incorrect: S31N is the adamantane M2 resistance mutation, not a baloxavir mechanism.
Option D: Option D is incorrect: PA-I38 substitutions arise as point substitutions selected during treatment, not through antigenic-shift reassortment.
Option E: Option E is incorrect: the substitutions reduce baloxavir binding affinity rather than abolishing endonuclease catalytic function; the virus continues to replicate, which is why prolonged shedding occurs.
6. The near-universal adamantane resistance among contemporary influenza A strains is attributed principally to one substitution. Which statement most precisely describes it?
A) A neuraminidase substitution at position 275 that contacts the active site differently for each drug
B) A serine-to-asparagine substitution at position 31 of the M2 transmembrane domain that disrupts adamantane binding while leaving proton-channel function essentially intact, imposing minimal fitness cost
C) A polymerase acidic subunit substitution at position 38 that reduces drug binding at the cap-dependent endonuclease
D) A hemagglutinin substitution that prevents binding of the drug to sialic acid receptors
E) A fusion-protein substitution that prevents the prefusion-to-postfusion conformational change
ANSWER: B
Rationale:
Adamantane resistance is driven principally by the serine-to-asparagine substitution at position 31 (S31N) in the M2 transmembrane domain; it disrupts adamantane binding without meaningfully impairing proton-channel function, so its fitness cost is minimal and it has spread to near-universal prevalence in circulating influenza A.
Option A: Option A is incorrect: a position-275 neuraminidase substitution describes H275Y, the oseltamivir resistance mutation, not adamantane resistance.
Option C: Option C is incorrect: a position-38 polymerase acidic subunit substitution describes baloxavir resistance.
Option D: Option D is incorrect: no clinically relevant hemagglutinin substitution is the basis of adamantane resistance, and adamantanes do not act at the sialic acid receptor.
Option E: Option E is incorrect: a fusion-protein conformational substitution pertains to respiratory syncytial virus biology, not influenza M2.
7. Aerosolized ribavirin is occasionally used for severe respiratory syncytial virus disease in immunocompromised patients. Which statement best characterizes ribavirin's pharmacology?
A) It is a humanized monoclonal antibody directed against the respiratory syncytial virus fusion protein
B) It is a single-dose oral polymerase acidic subunit endonuclease inhibitor
C) It selectively blocks the M2 ion channel of respiratory syncytial virus
D) It is a guanosine nucleoside analogue with multiple actions — competitive inhibition of inosine monophosphate dehydrogenase with depletion of guanosine triphosphate pools, direct inhibition of viral RNA-dependent RNA polymerase, and lethal mutagenesis — and is teratogenic, requiring respiratory protection for staff during administration
E) It is a peptidomimetic inhibitor of a viral main protease that requires a pharmacokinetic booster
ANSWER: D
Rationale:
Ribavirin is a synthetic guanosine nucleoside analogue with several mechanisms: competitive inhibition of inosine monophosphate dehydrogenase (depleting guanosine triphosphate pools), direct inhibition of viral RNA-dependent RNA polymerase, and lethal mutagenesis of the viral genome; it is teratogenic and embryotoxic, so staff of childbearing potential require respiratory protection during aerosol administration.
Option A: Option A is incorrect: a humanized anti-fusion-protein monoclonal antibody describes palivizumab (and nirsevimab), not ribavirin.
Option B: Option B is incorrect: a single-dose oral endonuclease inhibitor describes baloxavir.
Option C: Option C is incorrect: respiratory syncytial virus is not targeted by M2 ion-channel blockade, which pertains to influenza A adamantanes.
Option E: Option E is incorrect: a peptidomimetic main-protease inhibitor requiring a booster describes nirmatrelvir-ritonavir.
8. Which statement most precisely distinguishes nirsevimab from palivizumab?
A) Nirsevimab is an extended-half-life monoclonal antibody targeting a prefusion-specific epitope of the fusion protein, providing season-long protection from a single injection, whereas palivizumab targets the fusion protein but requires monthly dosing through the season
B) Nirsevimab is a small-molecule fusion inhibitor, whereas palivizumab is a nucleoside analogue
C) Nirsevimab treats established respiratory syncytial virus infection, whereas palivizumab is purely prophylactic
D) Nirsevimab targets the attachment glycoprotein, whereas palivizumab targets neuraminidase
E) Nirsevimab confers active immunity through B-cell stimulation, whereas palivizumab provides passive immunity
ANSWER: A
Rationale:
Both are monoclonal antibodies against the respiratory syncytial virus fusion protein, but nirsevimab is engineered with an extended-half-life Fc region and binds a prefusion-specific epitope, giving an entire season of protection from one injection; palivizumab requires monthly injections through the season.
Option B: Option B is incorrect: both are monoclonal antibodies, not a small-molecule inhibitor or a nucleoside analogue.
Option C: Option C is incorrect: both agents are prophylactic, not treatments for established disease.
Option D: Option D is incorrect: both target the fusion protein; neither targets the attachment glycoprotein or neuraminidase.
Option E: Option E is incorrect: both confer passive (antibody-mediated) immunity, not active immunity from B-cell stimulation.
9. Which statement most precisely describes the mechanism of the nirmatrelvir-ritonavir combination?
A) Nirmatrelvir is an adenosine analogue causing delayed chain termination, and ritonavir is a second polymerase inhibitor
B) Nirmatrelvir inhibits the cap-dependent endonuclease, and ritonavir inhibits neuraminidase
C) Both components are main-protease inhibitors acting additively at the same active site
D) Nirmatrelvir is a monoclonal antibody against the spike protein, and ritonavir prevents its renal clearance
E) Nirmatrelvir is a peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro, also called 3CLpro), and ritonavir is a pharmacokinetic booster that inhibits CYP3A4 and P-glycoprotein to raise and sustain nirmatrelvir concentrations
ANSWER: E
Rationale:
Nirmatrelvir is a peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro, also designated 3CLpro), which processes the viral polyprotein; ritonavir contributes little antiviral effect and serves as a pharmacokinetic booster by inhibiting CYP3A4 and P-glycoprotein, raising and sustaining nirmatrelvir levels.
Option A: Option A is incorrect: an adenosine analogue causing delayed chain termination describes remdesivir, and ritonavir is not a polymerase inhibitor.
Option B: Option B is incorrect: nirmatrelvir does not inhibit the influenza cap-dependent endonuclease, and ritonavir does not inhibit neuraminidase.
Option C: Option C is incorrect: ritonavir is not a main-protease inhibitor at therapeutic doses; it is a booster, so the two do not act additively at the same site.
Option D: Option D is incorrect: nirmatrelvir is a small-molecule protease inhibitor, not a monoclonal antibody, and ritonavir works by enzyme inhibition rather than blocking renal clearance.
10. Which statement most precisely describes the molecular mechanism of remdesivir?
A) Its catechol moiety chelates two metal ions in the cap-dependent endonuclease active site
B) It competitively occupies the neuraminidase catalytic site, preventing virion release
C) After intracellular activation to its triphosphate, it is incorporated by the RNA-dependent RNA polymerase and causes delayed chain termination approximately three nucleotides downstream, where its 1'-cyano group sterically clashes with the polymerase
D) It inhibits CYP3A4 to raise the plasma concentration of a co-administered protease inhibitor
E) It binds the M2 ion channel pore, blocking the proton influx required for uncoating
ANSWER: C
Rationale:
Remdesivir is a phosphoramidate prodrug of an adenosine analogue; activated to its triphosphate, it is incorporated by the viral RNA-dependent RNA polymerase and produces delayed chain termination roughly three nucleotides after incorporation, when its 1'-cyano group sterically clashes with the polymerase.
Option A: Option A is incorrect: catechol-mediated metal-ion chelation in the cap-dependent endonuclease describes baloxavir acid.
Option B: Option B is incorrect: competitive neuraminidase blockade describes the neuraminidase inhibitors.
Option D: Option D is incorrect: CYP3A4 inhibition to boost a protease inhibitor describes ritonavir.
Option E: Option E is incorrect: M2 pore blockade describes the adamantanes.
11. The influenza polymerase complex carries out cap-snatching. Which statement most precisely describes this process and its drug relevance?
A) Neuraminidase cleaves sialic acid to release virions, a step targeted by oseltamivir
B) The polymerase acidic subunit cleaves 5'-capped fragments from host pre-messenger RNA to prime synthesis of viral messenger RNA in the nucleus, and this endonuclease step is the target of baloxavir
C) The M2 ion channel transfers protons to prime the polymerase, a step targeted by amantadine
D) Hemagglutinin snatches host caps at the cell surface to initiate viral transcription, targeted by zanamivir
E) Reverse transcriptase copies the capped host RNA into viral DNA, a step targeted by ribavirin
ANSWER: B
Rationale:
In cap-snatching, the polymerase acidic subunit uses its cap-dependent endonuclease to cleave 5'-capped oligonucleotides from host pre-messenger RNA; these serve as primers for viral messenger RNA synthesis by the nuclear polymerase complex. Baloxavir blocks this endonuclease step.
Option A: Option A is incorrect: sialic acid cleavage for virion release is the neuraminidase/oseltamivir step, not cap-snatching.
Option C: Option C is incorrect: the M2 channel mediates proton influx for uncoating, not priming of the polymerase.
Option D: Option D is incorrect: hemagglutinin mediates attachment and fusion and does not perform cap-snatching; zanamivir targets neuraminidase.
Option E: Option E is incorrect: influenza is a negative-sense RNA virus that does not use reverse transcriptase, and ribavirin does not act on a reverse transcriptase here.
12. Which statement correctly distinguishes antigenic drift from antigenic shift in influenza?
A) Drift is reassortment of gene segments producing novel subtypes; shift is the gradual accumulation of point mutations
B) Both refer to the same process of progressive point mutation and differ only in rate
C) Drift occurs only in influenza B; shift occurs only in influenza A
D) Drift is the gradual accumulation of point mutations in hemagglutinin and neuraminidase under immune selection, necessitating annual vaccine reformulation; shift is the reassortment of gene segments between strains, producing novel subtypes with pandemic potential because population immunity is absent
Antigenic drift is the gradual accumulation of point mutations in the surface glycoproteins hemagglutinin and neuraminidase driven by immune selection, which is why vaccines are reformulated annually; antigenic shift is reassortment of gene segments between human and animal strains, generating novel subtypes against which pre-existing population immunity is absent, conferring pandemic potential.
Option A: Option A is incorrect: it reverses the two definitions.
Option B: Option B is incorrect: the processes are mechanistically distinct (point mutation versus reassortment), not the same process at different rates.
Option C: Option C is incorrect: drift and shift are not partitioned by influenza type in this way; shift in particular is an influenza A phenomenon, and drift affects circulating A and B.
Option E: Option E is incorrect: drift and shift describe antigenic change, not direct determinants of antiviral drug susceptibility.
13. A patient with confirmed influenza presents on day 4 of illness. Which statement best reflects current recommendations on antiviral initiation by clinical context?
A) Antiviral treatment is still indicated despite presentation beyond 48 hours if the patient is hospitalized, has severe or progressive illness, or is at high risk, because benefit persists in these groups regardless of symptom duration, whereas in otherwise healthy outpatients benefit diminishes after 48 hours
B) Antiviral treatment provides no benefit after 48 hours in any patient and should be withheld
C) Antiviral treatment after 48 hours is beneficial only in healthy outpatients and is contraindicated in hospitalized patients
D) Antiviral treatment confers durable immunity if given by day 4 and should be used for that purpose
E) Antiviral treatment should be deferred until day 7 to allow the viral peak to pass before intervening
ANSWER: A
Rationale:
Although early initiation maximizes benefit in healthy outpatients (where benefit diminishes after 48 hours), treatment is still recommended beyond 48 hours for hospitalized patients, those with severe or progressive illness, and high-risk patients, in whom clinical benefit persists regardless of symptom duration.
Option B: Option B is incorrect: benefit does not uniformly disappear after 48 hours; it persists in hospitalized and high-risk patients.
Option C: Option C is incorrect: this inverts the recommendation — hospitalized patients are precisely those who should be treated regardless of timing.
Option D: Option D is incorrect: antivirals do not confer immunity, which is the role of vaccination.
Option E: Option E is incorrect: deferring treatment to await the viral peak is contrary to the principle that earlier suppression of active replication is preferable.
14. Which statement most accurately states the general principle governing whether an antiviral resistance mutation spreads through a viral population?
A) Drug exposure induces de novo resistance mutations that would not otherwise exist in the population
B) Resistance spreads in direct proportion to the dose of drug administered, independent of viral biology
C) Resistance mutations spread only when they enhance viral replication relative to wild type
D) The presence of any resistance mutation guarantees population-wide spread regardless of replicative consequences
E) Error-prone polymerases generate preformed resistant variants before drug exposure; drug then selects them, and whether a given mutation spreads is determined chiefly by its fitness cost — the degree to which it impairs replication in the absence of drug
ANSWER: E
Rationale:
RNA viruses replicate with error-prone polymerases, so resistant variants exist within the quasispecies before any drug exposure; the drug selects rather than creates them. Whether a particular mutation spreads depends chiefly on its fitness cost — low-cost mutations such as S31N spread widely, while higher-cost mutations such as PA-I38 substitutions spread less.
Option A: Option A is incorrect: drug selects preexisting variants rather than inducing new ones.
Option B: Option B is incorrect: spread is governed by viral fitness, not simply by drug dose.
Option C: Option C is incorrect: most resistance mutations do not enhance replication; they spread when their fitness cost is low enough to permit transmission, not because they improve fitness.
Option D: Option D is incorrect: a mutation with a high fitness cost may persist poorly and fail to spread, so its presence does not guarantee population-wide spread.
15. Which statement most accurately summarizes baloxavir's approved clinical use and spectrum?
A) It is approved only for hospitalized patients requiring supplemental oxygen and is given intravenously over five days
B) It is active against influenza A but has no activity against influenza B
C) It is given as a single weight-based oral dose for acute uncomplicated influenza in patients aged five years and older symptomatic for no more than 48 hours, is active against both influenza A and B, and retains activity against oseltamivir-resistant strains carrying the H275Y mutation
D) It is contraindicated in any patient previously treated with a neuraminidase inhibitor
E) It must be combined with ritonavir to achieve adequate plasma concentrations
ANSWER: C
Rationale:
Baloxavir is given as a single weight-based oral dose for acute uncomplicated influenza in patients aged five years and older within 48 hours of symptom onset; it is active against both influenza A and B and retains activity against oseltamivir-resistant strains carrying H275Y because it acts at a different target (the polymerase acidic subunit endonuclease).
Option A: Option A is incorrect: that intravenous five-day, oxygen-requiring profile describes remdesivir, not baloxavir.
Option B: Option B is incorrect: baloxavir is active against both influenza A and B.
Option D: Option D is incorrect: prior neuraminidase inhibitor use is not a contraindication; baloxavir is in fact useful against neuraminidase inhibitor-resistant strains.
Option E: Option E is incorrect: baloxavir does not require a ritonavir booster; its long half-life supports single-dose therapy on its own.
16. Which statement best reflects special-population considerations among the influenza antivirals?
A) Zanamivir is preferred in patients with asthma because inhalation concentrates drug at the site of infection
B) Oseltamivir is the preferred agent in pregnancy, while inhaled zanamivir is generally avoided in patients with underlying airway disease because it can provoke bronchospasm
C) Baloxavir is the preferred agent in pregnancy because of its single-dose convenience
D) Amantadine is preferred in pregnant patients with influenza A because it avoids fetal exposure
E) Peramivir is contraindicated in hospitalized patients because it requires inhalation
ANSWER: B
Rationale:
Oseltamivir is preferred in pregnancy, where the most clinical experience exists, whereas inhaled zanamivir is generally avoided in patients with asthma or chronic obstructive pulmonary disease because it can provoke bronchospasm.
Option A: Option A is incorrect: the inhaled route is precisely why zanamivir is avoided in reactive airway disease, so it is not preferred in asthma.
Option C: Option C is incorrect: baloxavir is not recommended in pregnancy because of limited data; oseltamivir is preferred.
Option D: Option D is incorrect: amantadine is clinically obsolete for influenza because of universal resistance and is not a preferred agent in pregnancy.
Option E: Option E is incorrect: peramivir is an intravenous agent well suited to hospitalized patients who cannot take oral or inhaled drugs, not an inhaled agent.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.